Eqrx and abcellera announce collaboration to accelerate the advancement of new innovative medicines

Cambridge, mass. & vancouver, british columbia--(business wire)--eqrx, a company committed to developing and delivering important new medicines at radically lower prices, and abcellera (nasdaq: abcl), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration agreement for the discovery and development of therapeutic antibodies. the collaboration will leverage abcellera's ai-powered antibody discovery technology to search and
ABCL Ratings Summary
ABCL Quant Ranking